1. Home
  2. TOPS vs NEUP Comparison

TOPS vs NEUP Comparison

Compare TOPS & NEUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TOP Ships Inc.

TOPS

TOP Ships Inc.

HOLD

Current Price

$3.24

Market Cap

22.5M

ML Signal

HOLD

NEUP

Neuphoria Therapeutics Inc.

N/A

Current Price

$4.10

Market Cap

24.9M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
TOPS
NEUP
Founded
2000
1996
Country
Greece
United States
Employees
N/A
8
Industry
Marine Transportation
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
22.5M
24.9M
IPO Year
2004
N/A

Fundamental Metrics

Financial Performance
Metric
TOPS
NEUP
Price
$3.24
$4.10
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$21.00
AVG Volume (30 Days)
359.4K
56.9K
Earning Date
10-07-2025
02-17-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$9.90
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$2.14
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.08
$3.65
52 Week High
$11.47
$21.31

Technical Indicators

Market Signals
Indicator
TOPS
NEUP
Relative Strength Index (RSI) 38.27 37.59
Support Level $3.12 $4.01
Resistance Level $6.20 $4.56
Average True Range (ATR) 0.59 0.22
MACD 0.01 -0.07
Stochastic Oscillator 6.02 10.98

Price Performance

Historical Comparison
TOPS
NEUP

About TOPS TOP Ships Inc.

TOP Ships Inc owns tanker vessels throughout the world. The Company is an international owner and operator of modern, fuel-efficient eco tanker vessels focusing on the transportation of crude oil, petroleum products (clean and dirty), and bulk liquid chemicals. It generates revenue from the Time Charter agreements.

About NEUP Neuphoria Therapeutics Inc.

Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need.

Share on Social Networks: